2014 Annual Meeting | 8HC.001 - Neuromuscular Junction Disorders

Date Saturday 05/03/14

Time 08:00 AM - 12:00 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Half-Day Course

Director(s) Robert M. Pascuzzi, MD, FAAN

Topic(s)

Learning Objectives Participants should be familiar with the diagnosis and management of patients with myasthenia gravis and related disorders; learn to critically select therapies; and be able to distinguish myasthenia gravis, MuSK myasthenia, Lambert-Eaton syndrome, and recognize the less common diosorders of neuromuscular transmission.

CME Available No CME available

Core Competencies Patient Care & Procedural Skills, Professionalism, Medical Knowledge

Recommended Audience Trainee, General Neurologist, Specialist Neurologist

Teaching Styles Case-based, Didactic

Event Timeline
08:00 AM - 08:05 AM		Introduction Robert M. Pascuzzi, MD, FAAN
08:05 AM - 08:55 AM		Presentation and Diagnosis of Myasthenia Gravis: The Old and The New Janice M. Massey, MD, FAAN
08:55 AM - 09:45 AM		Treating Myasthenia Gravis in 2014: Evidence-based, Cost-effective, and New Developments Richard J. Barohn, MD, FAAN
09:45 AM - 09:55 AM		Discussion
09:55 AM - 10:10 AM		Break
10:10 AM - 11:00 AM		Toxins and Disorders of Neuromuscular Transmission Laura M. Tormoehlen, MD, FAAN
11:00 AM - 11:50 AM		Lambert-Eaton Syndrome and the Less Common Disorders of Neuromuscular Transmission Robert M. Pascuzzi, MD, FAAN
11:50 AM - 12:00 PM		Discussion

Faculty Disclosures
Robert M. Pascuzzi, MD, FAAN	Dr. Pascuzzi has nothing to disclose.
Richard J. Barohn, MD, FAAN	Dr. Barohn has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for NuFactor. The institution of Dr. Barohn has received research support from FDA OPD R01. Dr. Barohn has received intellectual property interests from a discovery or technology relating to health care.
Janice M. Massey, MD, FAAN	Dr. Massey has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenix. Dr. Massey has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Revance Therapeutics. Dr. Massey has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Momenta. The institution of Dr. Massey has received research support from Revance .
Laura M. Tormoehlen, MD, FAAN	The institution of Dr. Tormoehlen has received research support from Genentech. Dr. Tormoehlen has received publishing royalties from a publication relating to health care.